Sensitization to Molecular Components in 104 Atopic Dermatitis Patients in Relation to Subgroups of Patients Suffering from Bronchial Asthma and Allergic Rhinitis

Vaňková, R.; Čelakovská, Jarmila; Bukač, Josef; Krčmová, Irena; Krejsek, Jan; Andrýs, Ctirad

doi:10.14712/18059694.2020.59

Cited by 5 publications

(2 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…High levels of IgE exist in the serum of children with a combination of AS and AD, together with positive specific IgE antibodies [13]. Both allergic rhinitis and AS are known to belong to the same airway disease, and the most important pathogenesis is IgE‐mediated allergic reaction [14].…”

Section: Discussionmentioning

confidence: 99%

Exploration of the efficacy of anti‐immunoglobulin E monoclonal antibodies in the treatment of allergic asthma

Qian

Jiang

2022

Immunology

View full text Add to dashboard Cite

The present study aims to evaluate the efficacy of an anti‐immunoglobulin E monoclonal antibody (omalizumab) in the treatment of allergic asthma (AS). A total of 34 patients with moderate‐to‐severe bronchial asthma admitted to the Respiratory Department of Tianjin First Central Hospital between September 2019 and September 2021 were enrolled in this study. The patients were treated with omalizumab in addition to conventional inhaled corticosteroids + long‐acting β2 agonist treatment. The therapeutic effects before and after the addition of omalizumab were compared. The lung function indicators (ratio of the forced expiratory volume [FEV] in the first second to the forced vital capacity, FEV in the first second, forced expiratory flow [FEF] at 50% of vital capacity, FEF at 75% of vital capacity, and maximum mid‐expiratory flow), fractionated exhaled nitric oxide values, asthma control test scores, rhinoconjunctivitis quality of life questionnaire scores, and urticaria control test scores were significantly different after 4 months of the regular administration of omalizumab (p < 0.05) compared with before administration. The use of omalizumab had a significant efficacy in the treatment of patients with AS, and the effects were obvious in the subgroups of patients with a combination of AS and atopic dermatitis, chronic urticaria, and allergic rhinitis. These results indicate that the treatment is worthy of clinical promotion.

show abstract

Section: Discussionmentioning

confidence: 99%

Exploration of the efficacy of anti‐immunoglobulin E monoclonal antibodies in the treatment of allergic asthma

Qian

Jiang

2022

Immunology

View full text Add to dashboard Cite

show abstract

“…CRD is generally available in the United States and elsewhere. Some diagnostic modalities combine CRD and extract testing in the forms of ImmunoCAP ® Solid-phase Allergen Chip (ISAC) multiplex testing and ALEX ® Allergy Explorer (most widely used in Europe) which utilizes microarray technology to perform multiple simultaneous analyses (25,26). Although much more research is underway to determine clinical utility of CRD in other foods and allergic disease contexts, it is a promising advance with potential to enhance precision medicine in allergy.…”

Section: Precision Treatment In Allergymentioning

confidence: 99%

Achieving Precision Medicine in Allergic Disease: Progress and Challenges

2021

View full text Add to dashboard Cite

Allergic diseases (atopic dermatitis, food allergy, eosinophilic esophagitis, asthma and allergic rhinitis), perhaps more than many other traditionally grouped disorders, share several overlapping inflammatory pathways and risk factors, though we are still beginning to understand how the relevant patient and environmental factors uniquely shape each disease. Precision medicine is the concept of applying multiple levels of patient-specific data to tailor diagnoses and available treatments to the individual; ideally, a patient receives the right intervention at the right time, in order to maximize effectiveness but minimize morbidity, mortality and cost. While precision medicine in allergy is in its infancy, the recent success of biologics, development of tools focused on large data set integration and improved sampling methods are encouraging and demonstrates the utility of refining our understanding of allergic endotypes to improve therapies. Some of the biggest challenges to achieving precision medicine in allergy are characterizing allergic endotypes, understanding allergic multimorbidity relationships, contextualizing the impact of environmental exposures (the “exposome”) and ancestry/genetic risks, achieving actionable multi-omics integration, and using this information to develop adequately powered patient cohorts and refined clinical trials. In this paper, we highlight several recently developed tools and methods showing promise to realize the aspirational potential of precision medicine in allergic disease. We also outline current challenges, including exposome sampling and building the “knowledge network” with multi-omics integration.

show abstract

Association of atopic diseases with atrial fibrillation risk: A systematic review and meta-analysis

Zeng

Wang²,

Liang³

et al. 2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

BackgroundAtopic diseases and atrial fibrillation (AF) seem to share an underlying inflammatory pathology. To date, some population-based studies have explored the relationship between the two. We aimed to conduct a meta-analysis to examine the role of atopic condition in AF risk.MethodsAll relevant observational studies in PubMed and EMBASE databases up to November 2021 were searched. In RevMan 5.3, we used random-effects or fixed-effects models to pool the effect sizes of hazard ratio (HR), odds ratio (OR) and their corresponding 95% confidence intervals (95% CI). In addition, I2 and Cochran Q test were used to evaluate the heterogeneity.ResultsA total of 2488 records were retrieved. After screening according to the predetermined criteria, 6 cohort studies and 2 case-control studies were included in this meta-analysis. Herein, the meta-analysis of 6 cohort studies suggested that atopic diseases potentially increased the AF risk with the pooled HR of 1.26 (95%CI,1.14–1.39), while the pooled effect size (OR, 1.04; 95%CI,0.74–1.46) of 2 case-control studies was not statistically significant. Based on the types of atopic diseases, further subgroup analyses of 6 cohort studies revealed that asthma, allergic rhinitis, and atopic dermatitis all potentially increased the risk of subsequent AF with the pooled HR of 1.41 (n = 4; 95%CI, 1.25–1.58), 1.12 (n = 1; 95%CI,1.10–1.14) and 1.06 (n = 3; 95%CI, 1.01–1.12), respectively.ConclusionThis meta-analysis demonstrated that patients with atopic diseases have a higher risk of developing AF, particularly those with asthma.

show abstract

Sensitization to Molecular Components in 104 Atopic Dermatitis Patients in Relation to Subgroups of Patients Suffering from Bronchial Asthma and Allergic Rhinitis

Cited by 5 publications

References 57 publications

Exploration of the efficacy of anti‐immunoglobulin E monoclonal antibodies in the treatment of allergic asthma

Exploration of the efficacy of anti‐immunoglobulin E monoclonal antibodies in the treatment of allergic asthma

Achieving Precision Medicine in Allergic Disease: Progress and Challenges

Association of atopic diseases with atrial fibrillation risk: A systematic review and meta-analysis

Contact Info

Product

Resources

About